ADMA Biologics may be the best-kept secret on the IBD 50 list of growth stocks, but you could say it's hiding in plain sight. The biotech firm has been there since its debut on the screen Aug. 9 — without much fanfare — and continues to lead with strong stock performance and top-notch fundamentals. ADMA Biologics has a best-possible 99 IBD Composite Rating. And its 99 Relative Strength Rating even outperforms powerhouse Nvidia's 98 RS Rating. Read More...
ADMA Biologics may be the best-kept secret on the IBD 50 list of growth stocks, but you could say it’s hiding in plain sight. The biotech firm has been there since its debut on the screen Aug. 9 — without much fanfare — and continues to lead with strong stock performance and top-notch fundamentals. ADMA Biologics has a best-possible 99 IBD Composite Rating. And its 99 Relative Strength Rating even outperforms powerhouse Nvidia’s 98 RS Rating.
